Viewing Study NCT04807595


Ignite Creation Date: 2025-12-24 @ 1:13 PM
Ignite Modification Date: 2025-12-30 @ 8:44 PM
Study NCT ID: NCT04807595
Status: COMPLETED
Last Update Posted: 2023-03-06
First Post: 2021-03-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module